Clinical Trial

Angiogenic Imaging in Pulmonary Arterial Hypertension

Study Description

Angiogenic Imaging in Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a disorder of elevated pulmonary vascular resistance characterized by progressive remodeling and obliteration of vessels of the distal pulmonary circulation. Outcomes in PAH could be improved with earlier diagnosis, and with the early deployment of therapies before irreversible changes have occurred. This study tests the sensitivity of positron emission tomography (PET)-CT scanning with [89Zr]-bevacizumab, a radioisotope-conjugated anti-VEGF antibody for detecting pulmonary vascular remodeling in PAH disease. This test could enable non-invasive diagnosis early in the course of the disease, and potentially improve outcomes in PAH,

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Diagnostic Test - PET-CT Imaging with [89Zr]-bevacizumab

Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.

Additional Information

Official Study Title

Angiogenic Imaging in Pulmonary Arterial Hypertension

Clinical Trial ID

NCT03166306

ParticipAid ID

6dBMXb